On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure

BACKGROUND: Trials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have been observed in patients without overt heart failure, but it is unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennell, DJ, Carpenter, JP, Roughton, M, Cabantchik, ZI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180261/
https://www.ncbi.nlm.nih.gov/pubmed/21910880
http://dx.doi.org/10.1186/1532-429X-13-45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180261/
https://www.ncbi.nlm.nih.gov/pubmed/21910880
http://dx.doi.org/10.1186/1532-429X-13-45

Ejemplares similares